Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics Highlights MYQORZO Launch Progress, Teases 2026 Phase 3 Readout at Needham Conference
03:35am, Wednesday, 15'th Apr 2026
Cytokinetics (NASDAQ: CYTK) executives outlined early commercialization efforts for MYQORZO and previewed several upcoming clinical and regulatory milestones during a fireside chat at Needham's 25th A
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
04:00pm, Monday, 06'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of “Moderate Buy” from Brokerages
02:27am, Saturday, 28'th Mar 2026
Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-one ratings firms that are presently covering the firm, Marketbeat rep
Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?
12:32pm, Thursday, 26'th Mar 2026
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Wednesday, 18'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 13, 2026 it granted stock options to purchase an aggregate of 8,
Bamco Inc. NY Makes New Investment in Cytokinetics, Incorporated $CYTK
03:36am, Tuesday, 17'th Mar 2026
Bamco Inc. NY purchased a new stake in Cytokinetics, Incorporated (NASDAQ: CYTK) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Excha
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
08:00am, Monday, 16'th Mar 2026
New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics
Cinctive Capital Management LP Takes Position in Cytokinetics, Incorporated $CYTK
06:42am, Monday, 16'th Mar 2026
Cinctive Capital Management LP purchased a new position in Cytokinetics, Incorporated (NASDAQ: CYTK) during the undefined quarter, according to its most recent Form 13F filing with the Securities and
Bridgefront Capital LLC Invests $572,000 in Cytokinetics, Incorporated $CYTK
06:00am, Monday, 16'th Mar 2026
Bridgefront Capital LLC purchased a new position in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) during the undefined quarter, according to the company in its most recent filing with the Securi
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab
02:02am, Sunday, 15'th Mar 2026
Cytokinetics (NASDAQ: CYTK) executives told investors at the Barclays healthcare conference that the company's U.S. launch of MYQORZO is still in its earliest phase but showing what management describ
Cytokinetics, Incorporated $CYTK Shares Acquired by Capital International Investors
04:12am, Thursday, 12'th Mar 2026
Capital International Investors increased its holdings in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) by 0.9% during the third quarter, according to its most recent filing with the Securities
Cytokinetics, Incorporated (CYTK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
04:12pm, Wednesday, 11'th Mar 2026
Cytokinetics, Incorporated (CYTK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
02:18pm, Monday, 09'th Mar 2026
15,000 shares were sold for a transaction value of approximately $928,950 at a weighted average price of around $61.93 per share on Feb. 5, 2026. The sale accounted for 22.9% of Andrew Callos' direct
Fisher Asset Management LLC Raises Stock Holdings in Cytokinetics, Incorporated $CYTK
04:22am, Wednesday, 04'th Mar 2026
Fisher Asset Management LLC lifted its stake in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) by 3.8% during the third quarter, according to the company in its most recent disclosure with the Se
Cytokinetics to Participate in March Investor Conferences
04:00pm, Monday, 02'nd Mar 2026
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following
